Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

Determination of Susceptibilities of 26 Leptospira sp. Serovars to 24 Antimicrobial Agents by a Broth Microdilution Technique

Clinton K. Murray, Duane R. Hospenthal
Clinton K. Murray
Infectious Disease Service, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Duane R. Hospenthal
Infectious Disease Service, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Duane.Hospenthal@amedd.army.mil
DOI: 10.1128/AAC.48.10.4002-4005.2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The MICs of 24 antimicrobials for 26 Leptospira spp. serovars were determined using a broth microdilution technique. The MICs at which 90% of isolates tested were inhibited (MIC90s) of cefepime, imipenem-cilastatin, erythromycin, clarithromycin, and telithromycin were all ≤0.01 μg/ml. The MIC90s of amoxicillin, aztreonam, cefdinir, chloramphenicol, and penicillin G were ≥3.13 μg/ml. Many antimicrobials have excellent in vitro activity against Leptospira.

Leptospirosis is a worldwide zoonotic infection that is predominantly found in tropical climates. The genus Leptospira consists of 16 species and over 250 serovars, with the virulent strains producing infections that range from clinically inapparent to life threatening. The typical symptomatic presentation of leptospirosis is a mild febrile illness without pathognomonic findings. Definitive diagnosis relies upon either culture which has a low yield and requires incubation of 4 to 6 weeks or serological testing of acute- and convalescent-phase samples. Therefore, initial therapy of leptospirosis is often empirical, based upon a broad differential diagnosis that includes leptospirosis and other etiologies of acute febrile illness in the community.

Clinical trials of antimicrobial agents against leptospirosis are limited to penicillin, doxycycline, and ceftriaxone (4, 7, 11, 15). Although no survival benefit has been shown with these agents, symptom improvement, including resolution of fever and leptospiruria, has been documented. The ever-growing armamentarium of antimicrobial agents used as empirical therapies for acute febrile illnesses necessitates the assessment of newer antimicrobial agents against leptospirosis. In vitro antibiotic susceptibility testing, typically done on a limited scale using macrodilution techniques and small numbers of serovars, has been reported (3, 6, 8, 10, 12-14). We have developed an in vitro broth microdilution technique by which a more efficient evaluation of a greater number of antimicrobial agents and Leptospira serovars can be accomplished (9). In this study we assess the in vitro activity of 24 antimicrobial agents against 26 Leptospira serovars.

(This work was presented in part at the 52nd Annual Meeting of the American Society of Tropical Medicine and Hygiene, Philadelphia, Penn., December 2003.)

Twenty-six Leptospira serovars, representing seven species and 18 serogroups, were obtained from the Veterinary Command Food and Drug Analysis Laboratory, Fort Sam Houston, Texas (Table 1). These strains originated at the USDA National Veterinary Services Laboratories, Ames, Iowa. Although the majority of these were initially recovered from human infections, all have been maintained by subculture as laboratory strains for many years. The organisms were maintained and the inocula were prepared as previously described (9).

Broth microdilution susceptibility testing was performed as previously reported with antibiotic concentrations ranging from 25.0 to 0.01 μg/ml (U/ml for penicillin G) (9). Amoxicillin, ampicillin, cefotaxime, chloramphenicol, doxycycline, erythromycin, penicillin G, and tetracycline were purchased from Sigma-Aldrich (St. Louis, Mo.). Other antibiotics were obtained from their manufacturers (cefdinir and clarithromycin from Abbott Laboratories, Abbott Park, Ill.; telithromycin from Aventis, Bridgewater, N.J.; ciprofloxacin and moxifloxacin from Bayer Corporation, West Haven, Conn.; aztreonam, cefepime, garenoxacin, and gatifloxacin from Bristol-Myers Squibb, Wallingford, Conn.; ceftriaxone from Hoffmann-La Roche Inc., Nutley, N.J.; cefoxitin, ertapenem, imipenem, and cilastatin from Merck & Co., Inc., Rahway, N.J.; levofloxacin from Ortho-McNeil Pharmaceutical, Inc., Raritan, N.J.; and ampicillin, sulbactam, and azithromycin from Pfizer, Groton, Conn.). Ampicillin-sulbactam and imipenem-cilastatin were combined in 2:1 and 1:1 ratios, respectively, with the reported MICs being based on the concentration of the first agent in each combination. Each serovar-drug combination was tested in triplicate, and median MICs were used for comparisons. Cumulative susceptibility results across all serovars are expressed as MIC90, the concentration at which 90% of the Leptospira isolates are inhibited.

The median MICs from three experiments using the strains indicated in Table 1 are reported in Table 2. The observed reproducibility of drug-serovar combinations revealed that 84% (527 of 624) of test results fell within two dilutions of each other. The reproducibility increases to 94% if amoxicillin, ampicillin, and penicillin G are excluded from this comparison.

Ampicillin-sulbactam, the carbapenems, cefepime, cefotaxime, cefoxitin, ceftriaxone, the fluoroquinolones, the macrolides, and telithromycin all produced MIC90s of ≤0.39 μg/ml. Cefepime, clarithromycin, erythromycin, imipenem-cilastatin, erythromycin, and telithromycin were all found to have MIC90s below the limit of testing (≤0.01 μg/ml). The MIC90s of amoxicillin, aztreonam, cefdinir, chloramphenicol, and penicillin G across serovars were ≥3.13 μg/ml.

Delays inherent in the diagnosis of leptospirosis, a potentially fatal infection, often dictate empirical therapy for acute febrile illness. As the differential diagnosis of an acute febrile illness in any particular setting may be expansive, numerous antimicrobial agents are often used as initial therapies. Only three drugs have been evaluated for leptospirosis in randomized human trials (4, 7, 11, 15). Determination of the antileptospiral activity of newer agents is needed. Currently there is no standard method to assess in vitro antimicrobial agents for antileptospiral activity; however, we have recently described a broth microdilution method which is more rapid than the traditional macrodilution method (9). Our assessment by broth microdilution of 24 antimicrobial agents against 26 Leptospira serovars found that many antimicrobial agents have excellent in vitro activity.

Included in our testing were the traditional antileptospiral drugs penicillin G, ceftriaxone, and doxycycline and representative agents from many other classes of agents. As classes of antimicrobial agents, carbapenems, cephalosporins (with the exception of cefdinir), fluoroquinolones, and macrolides (and telithromycin) had lower MICs than the traditional agents. All agents with the exception of aztreonam had MICs equal to or less than that of penicillin G, the accepted treatment alternative for severe disease. The overall reproducibility seen in our study was excellent, although amoxicillin, ampicillin, and penicillin G had greater variability than the other antimicrobial agents tested. Serovar-specific diagnosis is virtually never available for therapy of acute infection, so an assortment of Leptospira spp. were included in our study to allow observation of potential strain-to-strain and species-to-species variability. We noted no clinically significant strain-to-strain or species-to-species variability.

A variety of antimicrobials have shown variable therapeutic activity in small in vitro and in vivo (animal) studies; however, these studies are limited by the numbers of antimicrobials and/or isolates of Leptospira spp. examined at one time (1-3, 5, 6, 8, 10, 12-14, 16). Through our broth microdilution study, we delivered reproducible results and allowed more convenient testing with greater throughput than previous macrodilution methods. Presently correlation of in vitro susceptibility to outcome is lacking in treatment trials for leptospirosis. Future study, including animal and human treatment or prophylaxis trials, can now be pursued to determine if any of these agents will be useful in the therapy of leptospirosis.

View this table:
  • View inline
  • View popup
TABLE 1.

Strains of Leptospira species tested for susceptibility to various antimicrobial agents

View this table:
  • View inline
  • View popup
TABLE 2.

Susceptibility of Leptospira strains to 24 antimicrobial agents or combinations of agents

ACKNOWLEDGMENTS

This work was supported in part by a grant from Abbott Laboratories.

The views expressed herein are those of the authors and do not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. government.

FOOTNOTES

    • Received 7 April 2004.
    • Returned for modification 6 June 2004.
    • Accepted 23 June 2004.
  • Copyright © 2004 American Society for Microbiology

REFERENCES

  1. 1.↵
    Alexander, A., and R. L. Rule. 1986. Penicillins, cephalosporins, and tetracyclines in treatment of hamsters with fatal leptospirosis. Antimicrob. Agents Chemother.30:835-839.
    OpenUrlAbstract/FREE Full Text
  2. 2.
    Alt, D. P., and C. A. Bolin. 1996. Preliminary evaluation of antimicrobial agents for treatment of Leptospira interrogans serovar pomona infection in hamsters and swine. Am. J. Vet. Res.57:59-62.
    OpenUrlPubMedWeb of Science
  3. 3.↵
    Broughton, E. S., and L. E. Flack. 1986. The susceptibility of a strain of Leptospira interrogans serogroup icterohaemorrhagiae to amoxycillin, erythromycin, lincomycin, tetracycline, oxytetracycline and minocycline. Zentbl. Bakteriol. Mikrobiol. Hyg. Ser. A261:425-431.
    OpenUrl
  4. 4.↵
    Edwards, C. N., G. D. Nicholson, T. A. Hassell, C. O. R. Everard, and J. Callender. 1988. Penicillin therapy in icteric leptospirosis. Am. J. Trop. Med. Hyg.39:388-390.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Faine, S., and W. J. Kaipainen. 1955. Erythromycin in experimental leptospirosis. J. Infect. Dis.57:146-151.
    OpenUrl
  6. 6.↵
    Hospenthal, D. R., and C. K. Murray. 2003. In vitro susceptibilities of seven Leptospira species to traditional and newer antibiotics. Antimicrob. Agents Chemother.47:2646-2648.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    McClain, B. L., W. R. Ballou, S. M. Harrison, and D. L. Steinweg. 1984. Doxycycline therapy for leptospirosis. Ann. Intern. Med.100:696-698.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    Murgia, R., and M. Cinco. 2001. Sensitivity of Borrelia and Leptospira to quinupristin-dalfopristin (Synercid) in vitro.New Microbiol.24:193-196.
    OpenUrlPubMed
  9. 9.↵
    Murray, C. K., and D. R. Hospenthal. 2004. Broth microdilution susceptibility testing for Leptospira spp. Antimicrob. Agents Chemother.48:1548-1552.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    Oie, S., K. Hironaga, A. Koshiro, H. Konishi, and Z. Yoshii. 1983. In vitro susceptibilities of five Leptospira strains to 16 antimicrobial agents. Antimicrob. Agents Chemother.24:905-908.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Panaphut, T., S. Domrongkitchaiporn, A. Vibhagool, B. Thinkamrop, and W. Susaengrat. 2003. Ceftriaxone compared with sodium penicillin G for treatment of severe leptospirosis. Clin. Infect. Dis.36:1507-1513.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    Prescott, J. 1991. Treatment of leptospirosis. Cornell Vet.81:7-12.
    OpenUrlPubMed
  13. 13.
    Shalit, I., A. Barnea, and A. Shahar. 1989. Efficacy of ciprofloxacin against Leptospira interrogans serogroup icterohaemorrhagiae. Antimicrob. Agents Chemother.33:788-789.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    Takashima, I., M. Ngoma, and N. Hashimoto. 1993. Antimicrobial effects of a new carboxyquinolone drug, Q-35, on five serogroups of Leptospira interrogans.Antimicrob. Agents Chemother.37:901-902.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Watt, G., L. P. Padre, M. L. Tuazon, C. Calubaquib, E. Santiago, C. P. Ranoa, and L. W. Laughlin. 1988. Placebo-controlled trial of intravenous penicillin for severe and late leptospirosis. Lancet1:433-435.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    Yoshimori, R. N., H. S. Goldberg, and D. C. Blenden. 1966. Cephalothin in the treatment of experimental leptospirosis in hamsters. Antimicrob. Agents Chemother.5:450-452.
    OpenUrl
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Determination of Susceptibilities of 26 Leptospira sp. Serovars to 24 Antimicrobial Agents by a Broth Microdilution Technique
Clinton K. Murray, Duane R. Hospenthal
Antimicrobial Agents and Chemotherapy Sep 2004, 48 (10) 4002-4005; DOI: 10.1128/AAC.48.10.4002-4005.2004

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Determination of Susceptibilities of 26 Leptospira sp. Serovars to 24 Antimicrobial Agents by a Broth Microdilution Technique
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Determination of Susceptibilities of 26 Leptospira sp. Serovars to 24 Antimicrobial Agents by a Broth Microdilution Technique
Clinton K. Murray, Duane R. Hospenthal
Antimicrobial Agents and Chemotherapy Sep 2004, 48 (10) 4002-4005; DOI: 10.1128/AAC.48.10.4002-4005.2004
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
Leptospira
leptospirosis

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596